Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CARM1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CARM1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CARM1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CARM1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003314310 | Thyroid | PTC | regulation of intracellular steroid hormone receptor signaling pathway | 42/5968 | 74/18723 | 8.40e-06 | 9.62e-05 | 42 |
GO:004544418 | Thyroid | PTC | fat cell differentiation | 102/5968 | 229/18723 | 3.66e-05 | 3.40e-04 | 102 |
GO:001657110 | Thyroid | PTC | histone methylation | 67/5968 | 141/18723 | 7.31e-05 | 6.31e-04 | 67 |
GO:000647910 | Thyroid | PTC | protein methylation | 82/5968 | 181/18723 | 1.01e-04 | 8.21e-04 | 82 |
GO:000821310 | Thyroid | PTC | protein alkylation | 82/5968 | 181/18723 | 1.01e-04 | 8.21e-04 | 82 |
GO:00313459 | Thyroid | PTC | negative regulation of cell projection organization | 83/5968 | 186/18723 | 1.72e-04 | 1.32e-03 | 83 |
GO:190521411 | Thyroid | PTC | regulation of RNA binding | 10/5968 | 12/18723 | 3.59e-04 | 2.44e-03 | 10 |
GO:00109778 | Thyroid | PTC | negative regulation of neuron projection development | 63/5968 | 137/18723 | 3.70e-04 | 2.50e-03 | 63 |
GO:00322594 | Thyroid | PTC | methylation | 146/5968 | 364/18723 | 4.99e-04 | 3.26e-03 | 146 |
GO:00434145 | Thyroid | PTC | macromolecule methylation | 127/5968 | 316/18723 | 1.02e-03 | 6.07e-03 | 127 |
GO:004560015 | Thyroid | PTC | positive regulation of fat cell differentiation | 33/5968 | 66/18723 | 1.63e-03 | 9.01e-03 | 33 |
GO:00305209 | Thyroid | PTC | intracellular estrogen receptor signaling pathway | 28/5968 | 54/18723 | 1.79e-03 | 9.68e-03 | 28 |
GO:000975519 | Thyroid | PTC | hormone-mediated signaling pathway | 80/5968 | 190/18723 | 1.84e-03 | 9.91e-03 | 80 |
GO:0051591111 | Thyroid | PTC | response to cAMP | 43/5968 | 93/18723 | 2.59e-03 | 1.33e-02 | 43 |
GO:00331464 | Thyroid | PTC | regulation of intracellular estrogen receptor signaling pathway | 19/5968 | 35/18723 | 4.94e-03 | 2.29e-02 | 19 |
GO:004559814 | Thyroid | PTC | regulation of fat cell differentiation | 59/5968 | 139/18723 | 5.50e-03 | 2.50e-02 | 59 |
GO:00507735 | Thyroid | PTC | regulation of dendrite development | 45/5968 | 103/18723 | 7.70e-03 | 3.27e-02 | 45 |
GO:005109834 | Thyroid | ATC | regulation of binding | 203/6293 | 363/18723 | 1.18e-18 | 1.55e-16 | 203 |
GO:001657017 | Thyroid | ATC | histone modification | 243/6293 | 463/18723 | 2.23e-17 | 2.27e-15 | 243 |
GO:001097523 | Thyroid | ATC | regulation of neuron projection development | 212/6293 | 445/18723 | 4.16e-10 | 1.14e-08 | 212 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CARM1 | SNV | Missense_Mutation | novel | c.687C>A | p.Asn229Lys | p.N229K | Q86X55 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-A8-A08S-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
CARM1 | SNV | Missense_Mutation | | c.608N>T | p.Ala203Val | p.A203V | Q86X55 | protein_coding | tolerated(0.74) | benign(0.111) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CARM1 | SNV | Missense_Mutation | | c.1560N>C | p.Leu520Phe | p.L520F | Q86X55 | protein_coding | deleterious_low_confidence(0.05) | probably_damaging(0.991) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CARM1 | SNV | Missense_Mutation | | c.950N>T | p.Ser317Phe | p.S317F | Q86X55 | protein_coding | deleterious(0.02) | probably_damaging(0.969) | TCGA-E9-A1RG-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | SD |
CARM1 | insertion | Nonsense_Mutation | novel | c.377_378insACAGGCATAAGCCACCGTGCCCGGCTTATTATTTCTTGTAGAGA | p.Cys127GlnfsTer3 | p.C127Qfs*3 | Q86X55 | protein_coding | | | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
CARM1 | SNV | Missense_Mutation | novel | c.1255N>T | p.Arg419Trp | p.R419W | Q86X55 | protein_coding | deleterious(0.01) | possibly_damaging(0.771) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CARM1 | SNV | Missense_Mutation | | c.330N>C | p.Gln110His | p.Q110H | Q86X55 | protein_coding | tolerated(0.09) | benign(0.106) | TCGA-JW-A5VI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | topotecan | PD |
CARM1 | SNV | Missense_Mutation | rs765573504 | c.1204N>A | p.Val402Met | p.V402M | Q86X55 | protein_coding | deleterious(0.01) | probably_damaging(0.957) | TCGA-A6-2672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
CARM1 | SNV | Missense_Mutation | | c.1430C>T | p.Thr477Met | p.T477M | Q86X55 | protein_coding | deleterious(0.01) | possibly_damaging(0.814) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CARM1 | SNV | Missense_Mutation | | c.1134N>T | p.Met378Ile | p.M378I | Q86X55 | protein_coding | tolerated(0.35) | benign(0.035) | TCGA-DM-A1HB-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
10498 | CARM1 | ENZYME, METHYL TRANSFERASE, DRUGGABLE GENOME | inhibitor | 336446915 | | |
10498 | CARM1 | ENZYME, METHYL TRANSFERASE, DRUGGABLE GENOME | | EOSIN | EOSIN | 18348515 |
10498 | CARM1 | ENZYME, METHYL TRANSFERASE, DRUGGABLE GENOME | inhibitor | 178103610 | | |
10498 | CARM1 | ENZYME, METHYL TRANSFERASE, DRUGGABLE GENOME | inhibitor | 310264736 | | |
10498 | CARM1 | ENZYME, METHYL TRANSFERASE, DRUGGABLE GENOME | inhibitor | 315661334 | | |
10498 | CARM1 | ENZYME, METHYL TRANSFERASE, DRUGGABLE GENOME | inhibitor | 178103609 | | |
10498 | CARM1 | ENZYME, METHYL TRANSFERASE, DRUGGABLE GENOME | inhibitor | 315661333 | BIIB021 | |